Skip to content Skip to footer
Subscribe Now

INSIGHTS+

New Drug Designations - March 2024
New Drug Designations – March 2024
Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, MHRA and EC. This month’s report includes designations allotted to 10 small molecules, 6 biologics, 5 cell & gene therapy, 1 recombinant fusion protein, 2 actineoplastics, 1 antidepressant, 1 drug conjugate, 1 analgesic and 6 devices    Trellis Bioscience's…
April 30, 2024
Know Your Investor (April Edition) OrbiMed Advisors
Know Your Investor (April Edition): OrbiMed Advisors
Shots: An American investment firm, OrbiMed Advisor is a prominent name when it comes to healthcare investments. The company boasts a robust portfolio of more than 180 companies, including AbCellera, Acelyrin, Actus Medical, and Adaptive Biotechnologies, among others In 2023, OrbiMed invested in 38 funding rounds; 11, 6, 9 & 12 every quarter across 2023…
April 24, 2024
Insights+ EMA Marketing Authorization of New Drugs in March 2024
Insights+: EMA Marketing Authorization of New Drugs in March 2024
Shots:  The EC approved 1 Biologic and 11 New Chemical Entities in March 2024, leading to treatments for patients and advances in the healthcare industry  In March 2024, the major highlighted drugs were Novartis’ Fabhalta to treat PNH and UCB’s Bimzelx for the treatment of Adults with Moderate to Severe Hidradenitis Suppurativa  PharmaShots has compiled…
April 22, 2024
Disease of the Month - Duchenne Muscular Dystrophy (DMD)
Disease of the Month – Duchenne Muscular Dystrophy (DMD)
Shots:  The Disease of the Month report by PharmaShots aims to integrate an advanced approach to disease analysis. The report delves deep into the epidemiology, market size, disease management, available therapies, and key players involved   For the April edition of the Disease of the Month report, PharmaShots brings an enlightening guide to Duchenne Muscular Dystrophy,…
April 17, 2024
Insights+ The US FDA New Drug Approvals in March 2024
Insights+: The US FDA New Drug Approvals in March 2024
Shots:  PharmaShots has compiled a list of US FDA-approved drugs in the month of March 2024  The US FDA approved a total of 14 drugs including 12 new molecular entities and 2 biologics leading to the treatments for patients and advances in the healthcare industry    The major highlighted drug was BeiGene’s Tevimbra for treating Advanced…
April 15, 2024
Insights+ Key Biosimilars Events of March 2024
Insights+ Key Biosimilars Events of March 2024
Shots:   Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency    Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients    During March, Sandoz received the US FDA’s approval for Wyost & Jubbonti.…
April 3, 2024
PharmaShots' Key Highlights of First Quarter 2024
PharmaShots’ Key Highlights of First Quarter 2024
Shots: The first quarter of 2024 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The highlight of the quarter was Gilead's acquisition of CymaBay Therapeutics for an aggregate of ~$4.3B This quarter also showcased multiple clinical trial results including Axsome Therapeutics P-III results for AXS-12 and BMS'…
April 1, 2024
New Drug Designations - February 2024
New Drug Designations – February 2024
Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, and EC. This month’s report includes designations allotted to 13 small molecules, 20 biologics, and 2 devices  SN Bioscience’s SNB-101 received ODD from the US FDA for the treatment of pancreatic cancer based on preclinical results. It…
March 28, 2024
Know Your Investor (March Edition) Qiming Venture Partners
Know Your Investor (March Edition): Qiming Venture Partners
Shots: In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…
March 26, 2024
Insights+ EMA Marketing Authorization of New Drugs in February 2024
Insights+: EMA Marketing Authorization of New Drugs in February 2024
Shots: The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis PharmaShots has compiled a list of a total…
March 20, 2024
Load more